Larimar Therapeutics Inc. (ZA71)
XDUS 
Summary
ZA71 Chart
Investors Buy Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR)
Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) was the target of some unusual options trading activity on Friday. Investors purchased 3,011 call options on the company. This represents an increase of approximately 250% compared to the average daily volume of 861 call options. Larimar Therapeutics Stock Down 3.8% Larimar Therapeutics stock opened at $4.59
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug nomlabofusp and backs a potential accelerated path.
Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care
Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path for its lead asset. Nomlabofusp directly addresses Friedreich's Ataxia's root cause, with a mechanism that delivers missing frataxin, potentially supplanting current standard-of-care. Anaphylaxis concerns have been mitigated by new dosing protocols and FDA-approved trial modifications, positioning LRMR for a potential re-rating.
Larimar Therapeutics Inc. (ZA71) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Larimar Therapeutics Inc. ever had a stock split?
Larimar Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Carole S. Ben-Maimon CEO | XDUS Exchange | US5171251003 ISIN |
| US Country | 65 Employees | - Last Dividend | 29 May 2020 Last Split | 19 Jun 2014 IPO Date |
Overview
Larimar Therapeutics, Inc. is a pioneering clinical-stage biotechnology company dedicated to the development of innovative treatments for individuals afflicted with rare diseases. Leveraging their cutting-edge cell penetrating peptide technology platform, they aim to address some of the most challenging genetic disorders. The company is strategically headquartered in Bala Cynwyd, Pennsylvania, positioning itself in a vibrant biotechnological ecosystem. With a keen focus on advancing their pipeline through rigorous clinical trials, Larimar Therapeutics, Inc. strives to bring hope and novel therapeutic options to patients and families affected by rare conditions.
Products and Services
- CTI-1601
Larimar Therapeutics, Inc.’s forefront product candidate, CTI-1601, is currently under Phase 2 OLE (Open Label Extension) clinical trial. This investigative therapy targets Friedreich's ataxia – a rare, progressively debilitating, and life-threatening genetic disease. By harnessing the potential of their unique cell penetrating peptide technology, Larimar Therapeutics aims to address the underlying causes of this condition, offering a gleam of hope to patients and families desperately awaiting viable treatments. CTI-1601 exemplifies the company’s dedication to transforming the landscape of rare disease treatment with groundbreaking scientific advancements.
